National Bank of Canada FI Acquires 177,033 Shares of Stryker Co. (NYSE:SYK)

National Bank of Canada FI boosted its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 69.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 431,259 shares of the medical technology company's stock after buying an additional 177,033 shares during the quarter. National Bank of Canada FI owned approximately 0.11% of Stryker worth $155,277,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Kohmann Bosshard Financial Services LLC bought a new stake in Stryker in the 4th quarter valued at $25,000. Dunhill Financial LLC raised its position in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 37 shares during the period. Rakuten Securities Inc. raised its position in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC bought a new stake in shares of Stryker during the 4th quarter worth about $30,000. Finally, BankPlus Trust Department bought a new stake in shares of Stryker during the 4th quarter worth about $33,000. Institutional investors own 77.09% of the company's stock.

Stryker Price Performance

Shares of SYK traded down $22.01 during midday trading on Friday, hitting $346.14. The company's stock had a trading volume of 3,956,734 shares, compared to its average volume of 1,321,179. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a market capitalization of $132.12 billion, a price-to-earnings ratio of 44.61, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company's fifty day simple moving average is $381.69 and its two-hundred day simple moving average is $374.30.

Remove Ads

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the business earned $3.46 earnings per share. As a group, equities analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.97%. Stryker's dividend payout ratio is currently 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on SYK shares. Argus set a $450.00 price objective on shares of Stryker in a research report on Monday, February 3rd. JPMorgan Chase & Co. lifted their price target on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Wells Fargo & Company upped their price objective on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Stifel Nicolaus lifted their target price on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a report on Wednesday, January 29th. Finally, Canaccord Genuity Group upped their price target on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.